Full-Time
Collaborative platform for biopharmaceutical innovation
No salary listed
Senior, Expert
Birmingham, UK
Home-based role within the United Kingdom; ad hoc international travel required for events.
BioPhorum is a platform that connects professionals in the biopharmaceutical and medical device industries to enhance collaboration and drive progress. It offers a range of services to its members, including tools for environmental monitoring performance qualification (EMPQ), access to extractables data, and information on host cell proteins. Members, which include pharmaceutical companies, biotech firms, and regulatory bodies, pay membership fees to utilize these resources and gain insights into industry standards and regulatory requirements. What sets BioPhorum apart from its competitors is its focus on creating a collaborative environment where industry players can work together to tackle shared challenges and develop best practices. The main goal of BioPhorum is to help its members navigate regulatory complexities and accelerate the development of sustainable medicines.
Company Size
51-200
Company Stage
N/A
Total Funding
N/A
Headquarters
London, United Kingdom
Founded
2008
Help us improve and share your feedback! Did you find this helpful?
Flexible Work Hours
19 May 2025London, UKBioPhorum, the global organisation accelerating collaboration between biopharmaceutical and medical device industry leaders, is pleased to announce the appointment of Dr. Uwe Buecheler, as Non-Executive Director (NED) to its Board of Directors, effective May 19, 2025.Dr. Buecheler brings a wealth of experience and expertise in the biopharmaceutical industry, having held various leadership roles in development operations, strategic planning, and innovation. He has overseen more than 30 biologics launches, including several top global biopharmaceuticals and has held senior roles in regulatory affairs, CMC development, biosafety, quality, CDMO business and operations.Dr. Buecheler led the expansion of Boehringer Ingelheim's Global Operations Network in the US and China and pioneered the first Biologics MAH approval in Shanghai. He also contributed to major expansion projects in aseptic processing, microbial manufacturing, and large-scale mammalian cell culture operations
BioPhorum acquires training organisation Brookwood Global.
BioPhorum, the global organization accelerating collaboration between biopharmaceutical and medical device industry leaders, has today announced the acquisition of Brookwood Global, a UK-based provider of training and educational content for professionals operating in the field of clinical research.BioPhorum has been at the heart of the biopharmaceutical industry for more than 15 years. Trusted by leaders from across the industry, it enables them to work together in non-competitive, confidential settings to seek out solutions for the benefit of all. Its members are united by their drive to save and improve patient outcomes and they recognize BioPhorum as the engine room for change in their industry.Brookwood Global is a privately owned organization, based in the UK, that has been delivering professional development solutions in the fields of clinical research and drug safety since 1996. Brookwood has trained more than 100,000 clinical research staff from c. 120 countries worldwide.On announcing the acquisition, Deborah Kobewka, BioPhorum CEO, said “We are delighted to be joining forces with the team at Brookwood. Their expertise in digital training integrates perfectly with our advanced knowledge of the biopharmaceutical and life sciences industries, creating opportunities for diversification and growth for both organizations.“The relationship also provides BioPhorum with the opportunity to expand our unique proposition into adjacent and connected segments of the pharmaceutical process/value chain, and to develop new services that will help our members derive maximum value from their relationship with us
Vespa Capital portfolio company SelectScience will next week launch the Virtual Biopharmaceutical Summit 2022 in partnership with BioPhorum.
With increasingly complex therapeutics arriving almost monthly, efficient technology transfer between biopharma and manufacturers is more important than ever. Ken Forman, senior director of product strategy at IDBS, explains how good digital strategies can avoid common pitfalls in the tech transfer process. Biopharmaceutical lifecycle management (BPLM) is the key to delivering novel therapies and lifesaving drugs to the world. It encapsulates every stage of drug development, including drug candidate identification, clinical trials establishing efficacy, manufacturing processes and supply chain activities for delivering these therapies to patients